Swedish Orphan Biovitrum AB (publ) (STO:SOBI)
Sweden
· Delayed Price · Currency is SEK | Market Cap | 98.23B |
| Revenue (ttm) | 26.24B |
| Net Income (ttm) | 3.96B |
| Shares Out | 343.46M |
| EPS (ttm) | 11.43 |
| PE Ratio | 25.03 |
| Forward PE | 18.60 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 353,907 |
| Average Volume | 325,578 |
| Open | 287.00 |
| Previous Close | 286.00 |
| Day's Range | 282.60 - 287.40 |
| 52-Week Range | 241.80 - 354.40 |
| Beta | 0.23 |
| RSI | 45.72 |
| Earnings Date | Jul 16, 2025 |
About STO:SOBI
Swedish Orphan Biovitrum AB (publ), a biopharma company, provides medicines in the areas of haematology, immunology, and specialty care in Europe, North America, the Middle East, Asia, and Australia. The company operates through three segments: Haematology, Immunology, and Specialty Care. It offers Alprolix for haemophilia B; ALTUVOCT for the treatment and prophylaxis of bleeding in patients with haemophilia A; Aspaveli/Empaveli for treating adult patients with paroxysmal nocturnal haemoglobinuria; Doptelet for the treatment of immune thrombocy... [Read more]
Full Company ProfileFinancial Performance
In 2024, STO:SOBI's revenue was 26.03 billion, an increase of 17.65% compared to the previous year's 22.12 billion. Earnings were 3.89 billion, an increase of 61.27%.
Financial StatementsNews
Apellis signs royalty purchase deal with Sobi for Aspaveli
Swedish Orphan Biovitrum: Haematology Focus Seems To Be Paying Off
BIOVF is moving from legacy products to a six-asset strategic portfolio that's mostly centered on Haematology. In particular, its Haematology segment contributed 71.6% of BIOVF's Q1 revenues, and five...
Swedish Orphan Biovitrum AB (BIOVF) Q1 2025 Earnings Call Transcript
Notice of Annual General Meeting in Swedish Orphan Biovitrum AB (publ)
STOCKHOLM , April 1, 2025 /PRNewswire/ -- The shareholders in Swedish Orphan Biovitrum AB (publ) (Sobi®) Reg. No. 556038-9321, are hereby summoned to the Annual General Meeting (the "Meeting"), to be ...
Ionis expands partnership with Sobi to include olezarsen commercialization outside the U.S.
Swedish Orphan Biovitrum targets high single-digit growth in 2025 amid robust pipeline advancements
Earnings Call Insights: Swedish Orphan Biovitrum (OTCPK:BIOVF) Q4 2024Management ViewCEO Guido Oelkers highlighted an 8% growth in Q4 revenues, driven...
Swedish Orphan Biovitrum AB (publ) (BIOVF) Q4 2024 Earnings Call Transcript
Swedish Orphan Biovitrum AB (publ) 2024 Q4 - Results - Earnings Call Presentation
Notice of Extraordinary General Meeting in Swedish Orphan Biovitrum AB (publ)
STOCKHOLM , Nov. 11, 2024 /PRNewswire/ -- The shareholders in Swedish Orphan Biovitrum AB (publ) (Sobi®) Reg. No. 556038-9321, are hereby summoned to the Extraordinary General Meeting (the "Meeting"),...
Swedish Orphan Biovitrum AB (publ) (BIOVF) Q3 2024 Earnings Call Transcript
Apellis Pharmaceuticals' Pegcetacoplan Meets Primary Goal In Late-Stage Study In Patients With Rare Kidney Diseases
Swedish Orphan Biovitrum AB (Sobi) (OTC: SWOBY) (OTC: BIOVF) and Apellis Pharmaceuticals, Inc . (NASDAQ: APLS) on Thursday released topline data results from Phase 3 VALIANT study of systemic pegce...
Swedish Orphan Biovitrum AB (publ) (BIOVF) Q2 2024 Earnings Call Transcript
Swedish Orphan Biovitrum AB (publ) (OTCPK:BIOVF) Q2 2024 Earnings Conference Call July 16, 2024 8:00 AM ET Company Participants Guido Oelkers - Chief Executive Officer Henrik Stenqvist - Chief Financi...
Swedish Orphan Biovitrum AB (publ) (BIOVF) Q1 2024 Earnings Call Transcript
Swedish Orphan Biovitrum AB (publ) (BIOVF) Q1 2024 Earnings Call Transcript
Notice of Annual General Meeting in Swedish Orphan Biovitrum AB (publ)
STOCKHOLM , April 4, 2024 /PRNewswire/ -- The shareholders in Swedish Orphan Biovitrum AB (publ) (Sobi®) Reg. No. 556038-9321, are hereby summoned to the Annual General Meeting (the "Meeting"), to be ...
Swedish Orphan Biovitrum AB (publ) (BIOVF) Q4 2023 Earnings Call Transcript
Swedish Orphan Biovitrum AB (publ) (BIOVF) Q4 2023 Earnings Call Transcript
Change in number of shares and votes in Swedish Orphan Biovitrum AB (publ)
STOCKHOLM , Nov. 30, 2023 /PRNewswire/ -- Swedish Orphan Biovitrum AB (publ) (Sobi®) (STO: SOBI) ("Sobi") has, as previously announced, carried out a share issue of series C shares, which has resulted...
Swedish Orphan Biovitrum AB (publ) (BIOVF) Q3 2023 Earnings Call Transcript
Swedish Orphan Biovitrum AB (publ) (BIOVF) Q3 2023 Earnings Call Transcript
Bulletin from Swedish Orphan Biovitrum (Sobi)'s Extraordinary General Meeting (EGM)
STOCKHOLM, Sweden , Aug. 15, 2023 /PRNewswire/ -- The Sobi® EGM was convened today on 15 August 2023. At the EGM, the shareholders, in accordance with the proposed resolutions, resolved as follows: Au...
Swedish Orphan Biovitrum AB (publ) (BIOVF) Q2 2023 Earnings Call Transcript
Swedish Orphan Biovitrum AB (publ) (OTCPK:BIOVF) Q2 2023 Results Conference Call July 18, 2023 7:00 AM ET Company Participants Guido Oelkers - Chief Executive Officer Henrik Stenqvist - Chief Financia...
Notice of Extraordinary General Meeting in Swedish Orphan Biovitrum AB (publ)
STOCKHOLM , July 18, 2023 /PRNewswire/ -- The shareholders in Swedish Orphan Biovitrum AB (publ) (Sobi®) Reg. No. 556038-9321, are hereby summoned to the Extraordinary General Meeting (the "Meeting"),...
New number of shares and votes in Swedish Orphan Biovitrum AB (publ)
STOCKHOLM , June 30, 2023 /PRNewswire/ -- As per 30 June 2023, the total number of shares in Swedish Orphan Biovitrum AB (publ) (Sobi®) amounts to 311,336,796 shares. All shares are common shares.
Swedish Orphan Biovitrum AB: Late-breaking efanesoctocog alfa data presented at ISTH demonstrates highly effective bleed protection in children with severe haemophilia A with once-weekly dosing
XTEND-Kids data confirms the efficacy and safety profile of efanesoctocog alfa with 50 IU/kg dosing in previously treated children as already shown in adults and adolescents. Factor VIII inhibitor dev...
CTI BioPharma Soars After Agreeing $1.7 Billion Sale. Biotech Deals Keep Coming.
Swedish Orphan Biovitrum will buy CTI for $9.10 a share as it looks to expand its rare hematology portfolio.
CTI BioPharma soars on deal news, while Upstart and Rivian climb after earnings
CTI BioPharma Corp. CTIC stock soared 83% in premarket trading after Swedish Orphan Biovitrum AB SE:SOBI said it had entered into an agreement to acquire the biotech in a deal valued at $1.7 billion. ...
Swedish Orphan Biovitrum to acquire CTI BioPharma in a deal valued at $1.7 billion
Swedish Orphan Biovitrum AB SE:SOBI on Wednesday announced that it has entered into an agreement to acquire U.S.-based CTI BioPharma Corp. CTIC in a deal valued at $1.7 billion. The Stockholm-based dr...